Results of the CALGB 40502 Study in TNBC

February 14, 2018
Lisa A. Carey, MD

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer, a randomized phase III trial of paclitaxel compared with nab-paclitaxel or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer.<br /> &nbsp;

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC), a randomized phase III trial of paclitaxel compared with nab-paclitaxel (Abraxane) or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.

There were a few noteworthy findings in the updated results reported at the 2017 San Antonio Breast Cancer Symposium, Carey notes. The original finding of an improvement in progression-free survival with paclitacel or nab-paclitaxel over ixabepilone held true, and this translated into an overall survival advantage.